Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Porras, Carolina ^a   Hildesheim, Allan ^b   González, Paula ^a,d   Schiffman, Mark ^b   Rodríguez, Ana Cecilia ^a   Wacholder, Sholom ^b   Jiménez, Silvia ^a   Quint, Wim ^c   Guillen, Diego ^a   Kreimer, Aimée R ^b   Herrero, Rolando ^d   Lowy, Douglas R ^b  

^a PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Manager Development and Diagnostic Services (DDS)   (Netherlands)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; CERVICAL SPECIMEN; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY ANALYSIS; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; UTERINE CERVIX CANCER; AGED; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT ANALYSIS; COLPOSCOPY; COSTA RICA; EARLY CANCER DIAGNOSIS; GENETICS; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MASS SCREENING; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

VIRUS DNA; WART VIRUS VACCINE;

ADULT; AGED; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; COLPOSCOPY; COSTA RICA; CROSS-SECTIONAL STUDIES; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84930466336     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju400     Document Type: Article

References (37)

1. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol. 2009;10(4):321-322.
2. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
3. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315-324.
4. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132(10):810-819.
5. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764-1772.
6. Castle PE, Stoler MH, Wright TC Jr, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880-890.
7. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663-672.
8. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomaviruspositive, cytologically normal women over a 10-year period. Cancer Res. 2006;66(21):10630-10636.
9. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-1588.
10. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589-1597.
11. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78-88.
12. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249-257.
13. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385-1394.
14. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
15. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516-542.
16. Arriba LN, Enerson CL, Belinson S, et al. Mexican Cervical Cancer Screening Study II: acceptability of human papillomavirus self-sampler. Int J Gynecol Cancer. 2010;20(8):1415-1423.
17. Gravitt PE, Belinson JL, Salmeron J, et al. Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int J Cancer. 2011;129(3):517-527.
18. Scarinci IC, Litton AG, Garces-Palacio IC, et al. Acceptability and usability of self-collected sampling for HPV testing among African-American women living in the Mississippi Delta. Womens Health Issues. 2013;23(2):e123-e130.
19. Petignat P, Faltin DL, Bruchim I, et al. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol. 2007;105(2):530-535.
20. Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on self-collected versus cliniciancollected samples: a meta-analysis. Lancet Oncol. 2014;15(2):172-183.
21. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet. 2011;378(9806):1868-1873.
22. Snijders PJ, Verhoef VM, Arbyn M, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer. 2013;132(10):2223-2236.
23. Arbyn M, Ronco G, Cuzick J, et al. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer. 2009;125(11):2489-2496.
24. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085-2092.
25. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat crosssectional study. Lancet Infect Dis. 2014;14(10):958-966.
26. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine. 2008;26(37):4795-4808.
27. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999;37(8):2508-2517.
28. van Doorn LJ, Molijn A, Kleter B, et al. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol. 2006;44(9):3292-3298.
29. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPVAssociated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136(10):1266-1297.
30. Tisnado DM, Adams JL, Liu H, et al. What is the concordance between the medical record and patient self-report as data sources for ambulatory care? Med Care. 2006;44(2):132-140.
31. Castle PE, Rodriguez AC, Porras C, et al. A comparison of cervical and vaginal human papillomavirus. Sex Transm Dis. 2007;34(11):849-855.
32. Gravitt PE, Lacey JV Jr, Brinton LA, et al. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev. 2001;10(2):95-100.
33. Cuzick J, Bergeron C, von Knebel Doeberitz M, et al. New technologies and procedures for cervical cancer screening. Vaccine 2012;30 Suppl 5:F107-F116.
34. Belinson JL, Du H, Yang B, et al. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing. Int J Cancer. 2012;130(8):1855-1860.
35. Brotherton JM, Tabrizi SN, Garland SM. Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance. Future Microbiol. 2012;7(2):193-199.
36. Porras C, Rodriguez AC, Hildesheim A, et al. Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiol Biomarkers Prev. 2009;18(3):863-865.
37. Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103(5):368-383.